-
1 Comment
Walvax Biotechnology Co., Ltd is currently in a long term uptrend where the price is trading 22.7% above its 200 day moving average.
From a valuation standpoint, the stock is 152.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 24.3.
Walvax Biotechnology Co., Ltd's total revenue rose by 323.9% to $1B since the same quarter in the previous year.
Its net income has increased by 2527.6% to $568M since the same quarter in the previous year.
Finally, its free cash flow fell by 15.2% to $-137M since the same quarter in the previous year.
Based on the above factors, Walvax Biotechnology Co., Ltd gets an overall score of 3/5.
| CurrencyCode | CNY |
|---|---|
| ISIN | CNE100000WN2 |
| Exchange | SHE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | 112.56 |
|---|---|
| Target Price | 10 |
| Dividend Yield | 0.1% |
| Market Cap | 16B |
| Beta | 0.91 |
Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300142.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
